Trial Profile
A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Pritelivir (Primary)
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- 16 Jan 2014 Results published in the New England Journal of Medicine.
- 16 Apr 2012 Results will be presented at the 2012 International Conference on Antiviral Research according to an AiCuris media release. Results will be presented at other international meetings also.
- 05 Sep 2011 Results of a 'resistance analysis' will be presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to an AiCuris media release.